Fig. 3From: A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitisAbsolute serum 7α-hydroxy-4-cholesten-3-one (C4) concentration at (a) baseline and 13 h after dosing on day 12, and (b) change from baseline to 13 h after dosing on day 12. Baseline was the last observation before the first dose of study drug. Data are from the pharmacodynamic analysis set. b.i.d., twice daily; CI, confidence interval; q.d., once daily; SD, standard deviationBack to article page